18:07 , May 9, 2018 |  BC Extra  |  Financial News

AxoGen raises $123M in upsized follow-on

AxoGen Inc. (NASDAQ:AXGN) raised $123 million through the sale of 3 million shares at $41 in an upsized follow-on underwritten by Jefferies, Leerink Partners, William Blair and JMP Securities. The price is a 5% discount...
07:00 , Aug 2, 1999 |  BC Week In Review  |  Clinical News

Antegren natalizumab: Phase II

Preliminary results from a 180-patient Phase II trial show the compound is ineffective at treating acute exacerbation in MS patients. The study analyzed patients receiving a single dose of Antegren within 96 hours of the...
07:00 , Apr 27, 1998 |  BC Week In Review  |  Clinical News

Neurobloc botulinum toxin type B: Phase III completed

ELN announced Phase III data in about 200 patients with cervical dystonia, with each of two trials achieving statistical significance for the end point of clinical improvement. Patients received a single injection of the botulinum...
08:00 , Nov 25, 1996 |  BioCentury  |  Finance

Mardi Gras

Five biotech financings closed on Tuesday, allowing the industry to fatten its reserves by $60.7 million. Two were IPOs - CV Therapeutics and Viropharma - which were scaled down considerably from the original filings. Even...
08:00 , Nov 4, 1996 |  BC Week In Review  |  Company News

Axogen Ltd., Elan deal

Elan created Axogen, a wholly owned R&D subsidiary, to develop products for neurological disorders, with an initial focus on multiple sclerosis. Axogen plans to raise $90 million through a unit offering consisting of American Depositary...